Q: Please evaluate Novocare as a potential growth stock. Comments I have read are below and it would be great to hear if you see potential for this to rise as we get back to treating "elective" issues.
Unfortunately, the pandemic has delayed enrollment in some clinical trials. But ultimately, this is the only company with a "fourth modality" of cancer treatment beyond surgery, radiation, and chemotherapy — and with no competitors in sight.
Thanks!
Unfortunately, the pandemic has delayed enrollment in some clinical trials. But ultimately, this is the only company with a "fourth modality" of cancer treatment beyond surgery, radiation, and chemotherapy — and with no competitors in sight.
Thanks!